Published in J Clin Psychiatry on October 01, 2007
Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry (2010) 2.56
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci (2011) 1.20
Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry (2011) 1.16
The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord (2011) 1.05
Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors. Future Neurol (2009) 0.98
Subthreshold bipolarity: diagnostic issues and challenges. Bipolar Disord (2011) 0.94
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol (2010) 0.89
Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry (2009) 0.88
Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues Clin Neurosci (2009) 0.85
Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs (2011) 0.84
Bipolar depression: clinically missed, pharmacologically mismanaged. Ther Adv Psychopharmacol (2011) 0.83
Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. J Affect Disord (2015) 0.83
The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 2: Review, grading of the evidence and a precise algorithm. Int J Neuropsychopharmacol (2016) 0.82
Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat (2012) 0.79
The noradrenaline metabolite MHPG is a candidate biomarker between the depressive, remission, and manic states in bipolar disorder I: two long-term naturalistic case reports. Neuropsychiatr Dis Treat (2015) 0.76
Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode. Neuropsychiatr Dis Treat (2016) 0.75
Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (Baltimore) (2016) 0.75
Possible manic switch induced by combination of bupropion and electroconvulsive therapy in recurrent unipolar depression: a case series. BMJ Case Rep (2009) 0.75
Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines. Medicine (Baltimore) (2016) 0.75
Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder. Psychiatry Investig (2010) 0.75
The bipolar spectrum. Indian J Psychol Med (2012) 0.75
A meta-analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder. Medicine (Baltimore) (2016) 0.75
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial. Ann Intern Med (2015) 6.66
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry (2006) 4.37
Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol (2013) 4.20
Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry (2002) 4.08
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2008) 3.82
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry (2005) 3.23
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry (2014) 2.82
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry (2013) 2.80
Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Arch Gen Psychiatry (2002) 2.70
Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry (2006) 2.69
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry (2002) 2.59
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2009) 2.39
Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry (2010) 2.39
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury. Crit Care Med (2002) 2.21
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry (2006) 2.19
Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry (2005) 2.13
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry (2004) 2.11
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. Am J Psychiatry (2011) 2.06
Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation. J Womens Health (Larchmt) (2015) 2.05
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2004) 2.04
Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. AIDS Behav (2009) 2.03
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry (2005) 1.99
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res (2013) 1.99
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2009) 1.96
Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology (2005) 1.93
The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry (2006) 1.93
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry (2007) 1.93
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry (2008) 1.92
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord (2009) 1.91
Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90
Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord (2009) 1.90
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord (2010) 1.90
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry (2007) 1.88
Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol (2007) 1.87
Reduction in the incidence of influenza A but not influenza B associated with use of hand sanitizer and cough hygiene in schools: a randomized controlled trial. Pediatr Infect Dis J (2011) 1.87
Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry (2004) 1.86